Table 2. Characteristic immunophenotypes... | American Society of Hematology

Table 2.

Characteristic immunophenotypes and levels of circulating Sézary cells

	EuroFlow-based gating strategy								Conventional gating strategies
SS case	Signature immunophenotype of dominant Sézary cell population	CD4⁺/ CD8⁺ T-cell ratio	Sézary cells, % of CD4⁺ T cells	CD4⁺CD26⁻, % of Sézary cells	CD4⁺CD7⁻, % of Sézary cells	Sézary counts, cells per µL	Sézary cells, % of lymphocytes	Sézary cells, % of leukocytes	CD4⁺CD26⁻, % of CD4⁺ T cells	CD4⁺CD26⁻ counts, cells per µL	CD4⁺CD7⁻, % of CD4⁺ T cells	CD4⁺CD7⁻ counts, cells per µL
1	CD3^lo CD4^lo CD2^lo/− CD7⁻ CD26^lo/− FSC^high	7.7	71.4	55.8	98.8	NP	47.9	6.12	42.4	NP	72.0	NP
2	CD45^lo CD3^lo CD4^lo CD5^lo CD26⁻	34.3	90.5	97.0	0.1	NP	79.6	33.65	94.8	NP	2.7	NP
3	CD3^bright CD5^lo CD2^lo/− CD26^lo/−	21.0	88.6	88.2	1.3	NP	74.0	16.79	76.4	NP	3.0	NP
4	CD4^lo CD7⁻ CD26⁻	9.9	54.1	88.3	98.0	NP	41.1	4.72	64.1	NP	64.4	NP
5	CD3⁻ CD5^lo	4.1	56.9	1.1	32.4	NP	39.2	2.07	8.4	NP	26.4	NP
6	CD3^lo CD2^lo/− CD7^lo/− CD26^lo/−	14.1	86.5	73.2	96.4	NP	79.4	35.12	65.5	NP	84.2	NP
7	CD3^lo CD2^lo/− CD7^lo/− CD26^lo/− FSC^high	10.1	90.9	92.3	40.6	NP	78.3	31.78	89.9	NP	38.3	NP
8*	CD3^lo CD2^lo CD7^lo/− CD26⁻ FSC^high	10.6	37.5	97.2	61.1	NP	23.2	4.07	41.4	NP	28.9	NP
9	CD3^lo CD5^lo CD26⁻ FSC^high	3.1	34.5	95.1	1.4	217.2	21.7	3.71	72.2	453.6	29.0	182.4
10*	CD3^bright CD2^lo/- CD7⁻CD26⁻ FSC^high SCC^high	23.6	79.1	98.1	97.5	1 391.1	67.2	7.60	88.6	1 558.7	77.3	1 359.0
11	CD3^lo CD2^lo	11.7	24.6	7.4	2.8	NP	13.5	3.41	1.4	NP	1.2	NP
12*	CD3^lo CD4^lo CD2^lo CD26⁻	6.5	36.8	93.4	12.1	NP	21.5	2.61	54.2	NP	12.9	NP
13*	CD7⁻ CD26⁻	9.1	91.8	98.4	99.7	3 154.4	75.9	21.06	96.2	3 305.7	94.0	3 229.8
14*	CD3^lo CD4^lo CD7^lo/− CD26^lo/−	72.6	99.4	95.9	96.5	12 409.0	97.9	86.46	95.8	11 953.0	96.0	11 979.1
15	CD7^lo/− CD26^lo/−	194.5	99.5	95.4	99.9	1 998.4	90.8	16.17	94.2	1 892.9	99.6	2 001.3
16	CD26⁻ FSC^high	4.0	87.5	99.7	1.3	2 730.3	65.5	21.12	94.3	2 942.6	1.8	55.5
17*	CD45^lo CD4^lo CD5^bright CD2^lo/− CD7^lo/− CD26⁻	14.6	90.5	97.8	7.1	1 702.8	73.0	20.29	92.1	1 732.1	9.9	186.7
18	CD2^lo/− CD7^lo/− CD26^lo/−	30.2	99.0	97.9	13.2	10 113.0	94.1	60.47	96.6	9 874.1	13.6	1 394.4
19	CD3^lo CD4^lo CD2^lo/− CD7⁻ CD26⁻	1.1	6.3	100.0	100.0	8.2	2.1	0.15	14.1	18.4	20.8	27.2
20*	CD45^lo CD3^lo CD2^lo/− CD7^lo/−CD26^lo/− FSC^high	11.7	27.2	73.5	12.5	334.4	21.8	4.91	31.8	390.6	9.7	119.5
21	CD45^lo CD3^lo CD7^lo/− CD26⁻	40.3	91.8	99.5	69.1	8 403.7	82.9	57.94	94.3	8 624.5	69.9	5 942.3
22	CD45^lo CD3^lo CD2^lo/− CD7⁻ CD26⁻ FSC^high SCC^high	13.6	52.0	92.3	95.7	288.6	35.6	2.10	53.8	298.5	51.9	287.7
23*	CD3^bright CD4^lo CD2^lo/− CD7⁻ CD26⁻ FSC^high SCC^high	7.2	76.3	99.5	92.0	378.7	52.7	3.07	80.6	399.8	75.3	373.8
24	CD3^lo CD2^lo/− CD7^lo/− CD26^lo/−	7.7	48.6	90.0	93.8	764.0	36.5	6.73	59.3	932.7	47.9	754.2

	EuroFlow-based gating strategy								Conventional gating strategies
SS case	Signature immunophenotype of dominant Sézary cell population	CD4⁺/ CD8⁺ T-cell ratio	Sézary cells, % of CD4⁺ T cells	CD4⁺CD26⁻, % of Sézary cells	CD4⁺CD7⁻, % of Sézary cells	Sézary counts, cells per µL	Sézary cells, % of lymphocytes	Sézary cells, % of leukocytes	CD4⁺CD26⁻, % of CD4⁺ T cells	CD4⁺CD26⁻ counts, cells per µL	CD4⁺CD7⁻, % of CD4⁺ T cells	CD4⁺CD7⁻ counts, cells per µL
1	CD3^lo CD4^lo CD2^lo/− CD7⁻ CD26^lo/− FSC^high	7.7	71.4	55.8	98.8	NP	47.9	6.12	42.4	NP	72.0	NP
2	CD45^lo CD3^lo CD4^lo CD5^lo CD26⁻	34.3	90.5	97.0	0.1	NP	79.6	33.65	94.8	NP	2.7	NP
3	CD3^bright CD5^lo CD2^lo/− CD26^lo/−	21.0	88.6	88.2	1.3	NP	74.0	16.79	76.4	NP	3.0	NP
4	CD4^lo CD7⁻ CD26⁻	9.9	54.1	88.3	98.0	NP	41.1	4.72	64.1	NP	64.4	NP
5	CD3⁻ CD5^lo	4.1	56.9	1.1	32.4	NP	39.2	2.07	8.4	NP	26.4	NP
6	CD3^lo CD2^lo/− CD7^lo/− CD26^lo/−	14.1	86.5	73.2	96.4	NP	79.4	35.12	65.5	NP	84.2	NP
7	CD3^lo CD2^lo/− CD7^lo/− CD26^lo/− FSC^high	10.1	90.9	92.3	40.6	NP	78.3	31.78	89.9	NP	38.3	NP
8*	CD3^lo CD2^lo CD7^lo/− CD26⁻ FSC^high	10.6	37.5	97.2	61.1	NP	23.2	4.07	41.4	NP	28.9	NP
9	CD3^lo CD5^lo CD26⁻ FSC^high	3.1	34.5	95.1	1.4	217.2	21.7	3.71	72.2	453.6	29.0	182.4
10*	CD3^bright CD2^lo/- CD7⁻CD26⁻ FSC^high SCC^high	23.6	79.1	98.1	97.5	1 391.1	67.2	7.60	88.6	1 558.7	77.3	1 359.0
11	CD3^lo CD2^lo	11.7	24.6	7.4	2.8	NP	13.5	3.41	1.4	NP	1.2	NP
12*	CD3^lo CD4^lo CD2^lo CD26⁻	6.5	36.8	93.4	12.1	NP	21.5	2.61	54.2	NP	12.9	NP
13*	CD7⁻ CD26⁻	9.1	91.8	98.4	99.7	3 154.4	75.9	21.06	96.2	3 305.7	94.0	3 229.8
14*	CD3^lo CD4^lo CD7^lo/− CD26^lo/−	72.6	99.4	95.9	96.5	12 409.0	97.9	86.46	95.8	11 953.0	96.0	11 979.1
15	CD7^lo/− CD26^lo/−	194.5	99.5	95.4	99.9	1 998.4	90.8	16.17	94.2	1 892.9	99.6	2 001.3
16	CD26⁻ FSC^high	4.0	87.5	99.7	1.3	2 730.3	65.5	21.12	94.3	2 942.6	1.8	55.5
17*	CD45^lo CD4^lo CD5^bright CD2^lo/− CD7^lo/− CD26⁻	14.6	90.5	97.8	7.1	1 702.8	73.0	20.29	92.1	1 732.1	9.9	186.7
18	CD2^lo/− CD7^lo/− CD26^lo/−	30.2	99.0	97.9	13.2	10 113.0	94.1	60.47	96.6	9 874.1	13.6	1 394.4
19	CD3^lo CD4^lo CD2^lo/− CD7⁻ CD26⁻	1.1	6.3	100.0	100.0	8.2	2.1	0.15	14.1	18.4	20.8	27.2
20*	CD45^lo CD3^lo CD2^lo/− CD7^lo/−CD26^lo/− FSC^high	11.7	27.2	73.5	12.5	334.4	21.8	4.91	31.8	390.6	9.7	119.5
21	CD45^lo CD3^lo CD7^lo/− CD26⁻	40.3	91.8	99.5	69.1	8 403.7	82.9	57.94	94.3	8 624.5	69.9	5 942.3
22	CD45^lo CD3^lo CD2^lo/− CD7⁻ CD26⁻ FSC^high SCC^high	13.6	52.0	92.3	95.7	288.6	35.6	2.10	53.8	298.5	51.9	287.7
23*	CD3^bright CD4^lo CD2^lo/− CD7⁻ CD26⁻ FSC^high SCC^high	7.2	76.3	99.5	92.0	378.7	52.7	3.07	80.6	399.8	75.3	373.8
24	CD3^lo CD2^lo/− CD7^lo/− CD26^lo/−	7.7	48.6	90.0	93.8	764.0	36.5	6.73	59.3	932.7	47.9	754.2

The signature immunophenotypic profile is defined by markers that showed significant aberrancies and were essential for Sézary cell identification (LST, T-CLPD panels). Markers with minor shifts in mean fluorescence intensity on Sézary cell populations compared with normal CD4⁺ T cells and that were redundant or not sufficiently informative for the distinction between these populations are not mentioned. Sézary cell percentages and counts (T-CLPD panel) are given as identified by EuroFlow or conventional gating strategies (CD4⁺CD26⁻ or CD4⁺CD7⁻).

NP, not performed.

PB sample collected at the diagnostic stage.

View Large

This Feature Is Available To Subscribers Only